‘Excessive Pricing’ Inquiry Widens As EC’s First Antitrust Price Probe Targets Aspen Pharma
The litany of complaints against pharmaceutical companies for imposing “excessive” prices on generic drugs is growing after the European Commission decided to pursue Aspen Pharma over price rises imposed on a range of anticancer products it acquired from GSK.
You may also be interested in...
Commitments offered by Aspen Pharmacare last year to settle price-gouging allegations over six oncology drugs have been accepted by the European Commission.
After the European Commission adopted a preliminary assessment that Aspen Pharmacare “may have abused its dominant position by imposing unfair prices” for six mature oncology brands, the South African firm has outlined multiple commitments that would bring to a close a three-year Commission investigation across the EEA if adopted.
Newly passed UK legislation gives the government powers to curb pricing of unbranded generics when market forces fail. The Association of the British Pharmaceutical Industry has welcomed amendments to draft legislation that have addressed its concerns over onerous requirements.